{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:24:53Z","timestamp":1790727893628,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Fox Chase Cancer Center Board of Associates, Bucks County Chapter","award":["[Private Funding]"],"award-info":[{"award-number":["[Private Funding]"]}]},{"name":"United States Public Health Service","award":["P30CA006927"],"award-info":[{"award-number":["P30CA006927"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Preoperative delay when treating breast cancer confers poorer outcomes, but growth rates and the upstaging likelihoods per delay interval remain unknown. This study evaluated upstaging risk, nodal spread, and tumor growth rates in vivo while awaiting treatment.    <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods<\/jats:title>\n            <jats:p>Registry-based data from the national cancer database was reviewed for patients treated between 2010 and 2020 at commission on cancer-accredited facilities, with nonmetastatic, noninflammatory breast cancer, undergoing surgery first.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Among 1,018,219 patients, 11.5% had primary tumoral upstaging and 14.1% had nodal upstaging. For every 30 d between diagnosis and surgery, the adjusted odds ratios (ORs) for tumor upstaging was 1.11 for ductal carcinoma in situ (DCIS) (95% CI 1.09\u20131.13, <jats:italic>P\u2009<\/jats:italic>&lt;\u20090.0001), 1.13 for cT1 (95% CI 1.11\u20131.15, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001), and 1.18 for cT2 tumors (95% CI 1.15\u20131.21, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001). For invasive tumors, the adjusted 30-d ORs for upstaging in triple negative (TN) primaries were higher (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001) at 1.21 (95% CI 1.17\u20131.25) than hormone receptor-positive (HR+, 1.13; 95% CI 1.12\u20131.15) and human epidermal growth factor 2-positive (HER2+, 1.09; 95% CI 1.04\u20131.13). cN0 patients had an adjusted OR for upstaging to node-positive of 1.07 (95% CI 1.06\u20131.08, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001). The number of 30-d intervals for cT1a, cT1b, cT1c, and cT2 tumors to grow 1\u00a0mm was 3.95, 2.63, 2.27, and 1.92, respectively, with tumor growth faster in TN tumors (1.29) than HER2+ (4.95) or HR+ (2.35) (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Longer delays risk greater upstaging and nodal spread, explaining the association with higher disease-specific and overall mortality in prior studies. Larger and TN tumors have larger delay-associated upstaging likelihoods and in vivo growth rates, making preoperative delays more impactful in these groups.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1245\/s10434-025-17867-9","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T13:38:43Z","timestamp":1753277923000},"page":"8789-8797","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Breast Cancer Upstaging Risk and In Vivo Tumor Growth Rates Associated with Preoperative Delays"],"prefix":"10.1245","volume":"32","author":[{"given":"Richard J.","family":"Bleicher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen J.","family":"Ruth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin D.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric A.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea S.","family":"Porpiglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison A.","family":"Aggon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis R.","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"issue":"1","key":"17867_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin."},{"issue":"36","key":"17867_CR2","doi-asserted-by":"publisher","first-page":"4485","DOI":"10.1200\/JCO.2012.41.7972","volume":"30","author":"RJ Bleicher","year":"2012","unstructured":"Bleicher RJ, Ruth K, Sigurdson ER, et al. Preoperative delays in the US Medicare population with breast cancer. J Clin Oncol. 2012;30(36):4485\u201392.","journal-title":"J Clin Oncol."},{"issue":"1","key":"17867_CR3","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10549-016-3982-x","volume":"160","author":"TM Churilla","year":"2016","unstructured":"Churilla TM, Egleston BL, Murphy CT, et al. Patterns of multidisciplinary care in the management of non-metastatic invasive breast cancer in the United States Medicare patient. Breast Cancer Res Treat. 2016;160(1):153\u201362.","journal-title":"Breast Cancer Res Treat."},{"issue":"3","key":"17867_CR4","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10549-018-5046-x","volume":"173","author":"RJ Bleicher","year":"2019","unstructured":"Bleicher RJ, Chang C, Wang CE, et al. Treatment delays from transfers of care and their impact on breast cancer quality measures. Breast Cancer Res Treat. 2019;173(3):603\u201317.","journal-title":"Breast Cancer Res Treat."},{"issue":"3","key":"17867_CR5","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1001\/jamaoncol.2015.4508","volume":"2","author":"RJ Bleicher","year":"2016","unstructured":"Bleicher RJ, Ruth K, Sigurdson ER, et al. Time to surgery and breast cancer survival in the United States. JAMA Oncol. 2016;2(3):330\u20139.","journal-title":"JAMA Oncol."},{"issue":"5","key":"17867_CR6","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1245\/s10434-019-08050-y","volume":"27","author":"AM Mateo","year":"2020","unstructured":"Mateo AM, Mazor AM, Obeid E, et al. Time to surgery and the impact of delay in the non-neoadjuvant setting on triple-negative breast cancers and other phenotypes. Ann Surg Oncol. 2020;27(5):1679\u201392.","journal-title":"Ann Surg Oncol."},{"key":"17867_CR7","unstructured":"Commission on Cancer. NCDB Announces New Breast Quality Measure. 2022; https:\/\/www.facs.org\/for-medical-professionals\/news-publications\/news-and-articles\/cancer-programs-news\/063022\/ncdb-announces-new-breast-quality-measure\/. Accessed 30 June 2022."},{"issue":"2","key":"17867_CR8","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1539-6053.2008.00033.x","volume":"8","author":"G Gigerenzer","year":"2007","unstructured":"Gigerenzer G, Gaissmaier W, Kurz-Milcke E, Schwartz LM, Woloshin S. Helping doctors and patients make sense of health statistics. Psychol Sci Public Interest. 2007;8(2):53\u201396.","journal-title":"Psychol Sci Public Interest."},{"issue":"4","key":"17867_CR9","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1002\/1097-0142(197610)38:4<1826::AID-CNCR2820380460>3.0.CO;2-L","volume":"38","author":"AW Pearlman","year":"1976","unstructured":"Pearlman AW. Breast cancer\u2013influence of growth rate on prognosis and treatment evaluation: a study based on mastectomy scar recurrences. Cancer. 1976;38(4):1826\u201333.","journal-title":"Cancer."},{"issue":"6","key":"17867_CR10","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1002\/1097-0142(19930315)71:6<2020::AID-CNCR2820710616>3.0.CO;2-#","volume":"71","author":"JA Spratt","year":"1993","unstructured":"Spratt JA, Vonfournier D, Spratt JS, Weber EE. Mammographic assessment of human breast-cancer growth and duration. Cancer. 1993;71(6):2020\u20136.","journal-title":"Cancer."},{"issue":"12","key":"17867_CR11","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1001\/jamaoncol.2016.6905","volume":"3","author":"DJ Boffa","year":"2017","unstructured":"Boffa DJ, Rosen JE, Mallin K, et al. Using the national cancer database for outcomes research: a review. JAMA Oncol. 2017;3(12):1722\u20138.","journal-title":"JAMA Oncol."},{"issue":"4","key":"17867_CR12","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.amjsurg.2019.07.016","volume":"218","author":"JK Plichta","year":"2019","unstructured":"Plichta JK, Thomas SM, Sergesketter AR, et al. Clinical and pathological stage discordance among 433,514 breast cancer patients. Am J Surg. 2019;218(4):669\u201376.","journal-title":"Am J Surg."},{"issue":"1","key":"17867_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00000658-190707000-00001","volume":"46","author":"WSI Halsted","year":"1907","unstructured":"Halsted WSI. The results of radical operations for the cure of carcinoma of the breast. Ann Surg. 1907;46(1):1\u201319.","journal-title":"Ann Surg."},{"issue":"5","key":"17867_CR14","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1097\/00000658-192811000-00004","volume":"88","author":"WJ Potts","year":"1928","unstructured":"Potts WJ. Results of delay in treatment of breast cancer. Ann Surg. 1928;88(5):842\u20134.","journal-title":"Ann Surg."},{"issue":"10","key":"17867_CR15","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1245\/s10434-016-5486-7","volume":"23","author":"AC Polverini","year":"2016","unstructured":"Polverini AC, Nelson RA, Marcinkowski E, et al. Time to treatment: measuring quality breast cancer care. Ann Surg Oncol. 2016;23(10):3392\u2013402.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"17867_CR16","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s10549-021-06460-9","volume":"191","author":"CG Verdone","year":"2022","unstructured":"Verdone CG, Bayron JA, Chang C, et al. A tool to predict disparities in the timeliness of surgical treatment for breast cancer patients in the USA. Breast Cancer Res Treat. 2022;191(3):513\u201322.","journal-title":"Breast Cancer Res Treat."},{"issue":"4","key":"17867_CR17","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/jso.26332","volume":"123","author":"A Khader","year":"2021","unstructured":"Khader A, Chang SC, Santamaria-Barria J, et al. Delay in surgery is associated with axillary upstaging of clinically node negative breast cancer patients. J Surg Oncol. 2021;123(4):854\u201365.","journal-title":"J Surg Oncol."},{"issue":"8","key":"17867_CR18","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1002\/1097-0142(19800415)45:8<2198::AID-CNCR2820450832>3.0.CO;2-7","volume":"45","author":"D Vonfournier","year":"1980","unstructured":"Vonfournier D, Weber E, Hoeffken W, Bauer M, Kubli F, Barth V. Growth-rate of 147 mammary carcinomas. Cancer. 1980;45(8):2198\u2013207.","journal-title":"Cancer."},{"issue":"2","key":"17867_CR19","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ejso.2007.04.020","volume":"34","author":"RM Mann","year":"2008","unstructured":"Mann RM, Veltman J, Barentsz JO, Wobbes T, Blickman JG, Boetes C. The value of MRI compared to mammography in the assessment of tumour extent in invasive lobular carcinoma of the breast. Eur J Surg Oncol. 2008;34(2):135\u201342.","journal-title":"Eur J Surg Oncol."},{"issue":"6","key":"17867_CR20","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.2214\/AJR.04.1898","volume":"186","author":"M Bazzocchi","year":"2006","unstructured":"Bazzocchi M, Zuiani C, Panizza P, et al. Contrast-enhanced breast MRI in patients with suspicious microcalcifications on mammography: results of a multicenter trial. AJR Am J Roentgenol. 2006;186(6):1723\u201332.","journal-title":"AJR Am J Roentgenol."},{"issue":"Suppl 3","key":"17867_CR21","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1245\/s10434-010-1266-y","volume":"17","author":"LJ McGhan","year":"2010","unstructured":"McGhan LJ, Wasif N, Gray RJ, et al. Use of preoperative magnetic resonance imaging for invasive lobular cancer: good, better, but maybe not the best? Ann Surg Oncol. 2010;17(Suppl 3):255\u201362.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"17867_CR22","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.clinimag.2007.01.001","volume":"31","author":"T Caramella","year":"2007","unstructured":"Caramella T, Chapellier C, Ettore F, Raoust I, Chamorey E, Balu-Maestro C. Value of MRI in the surgical planning of invasive lobular breast carcinoma: a prospective and a retrospective study of 57 cases: comparison with physical examination, conventional imaging, and histology. Clinical Imaging May-Jun. 2007;31(3):155\u201361.","journal-title":"Clinical Imaging. May-Jun"},{"issue":"10","key":"17867_CR23","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1046\/j.1365-2168.2002.02208.x","volume":"89","author":"K Munot","year":"2002","unstructured":"Munot K, Dall B, Achuthan R, Parkin G, Lane S, Horgan K. Role of magnetic resonance imaging in the diagnosis and single-stage surgical resection of invasive lobular carcinoma of the breast. Br J Surg. 2002;89(10):1296\u2013301.","journal-title":"Br J Surg."},{"issue":"9869","key":"17867_CR24","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","volume":"381","author":"C Davies","year":"2013","unstructured":"Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805\u201316.","journal-title":"Lancet."},{"issue":"10191","key":"17867_CR25","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1016\/S0140-6736(19)30650-6","volume":"393","author":"HM Earl","year":"2019","unstructured":"Earl HM, Hiller L, Vallier AL, et al. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Lancet. 2019;393(10191):2599\u2013612.","journal-title":"Lancet."},{"issue":"2","key":"17867_CR26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1208\/s12248-019-0302-5","volume":"21","author":"K Kay","year":"2019","unstructured":"Kay K, Dolcy K, Bies R, Shah DK. Estimation of solid tumor doubling times from progression-free survival plots using a novel statistical approach. AAPS J. 2019;21(2):27.","journal-title":"AAPS J."},{"issue":"37","key":"17867_CR27","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000004874","volume":"95","author":"SH Lee","year":"2016","unstructured":"Lee SH, Kim YS, Han W, et al. Tumor growth rate of invasive breast cancers during wait times for surgery assessed by ultrasonography. Medicine (Baltimore). 2016;95(37):e4874.","journal-title":"Medicine (Baltimore)."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17867-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-17867-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17867-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T15:40:42Z","timestamp":1760715642000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-17867-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["17867"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-17867-9","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,23]]},"assertion":[{"value":"25 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no relevant conflicts of interest. Authors Bleicher, Williams, Aggon, and Porpiglia are consultants for Elucent Medical, Eden Prairie Minnesota, USA, a localization device company, which is unrelated to this work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}